Targeted Therapies for Kidney Cancer

VIDEO | 20:00

Six new targeted therapies have improved treatment for advanced, metastatic kidney cancer in recent years. These include anti-angiogenesis inhibitors, which destroy blood vessels that surround tumors, and mTOR inhibitors, which interfere with a process that fuels growth in cancer cells. As Memorial Sloan Kettering medical oncologist Robert Motzer explains, these new drugs have significantly increased survival for many patients and have fewer side effects than chemotherapy. Memorial Sloan Kettering’s multidisciplinary translational research team is working to develop new targeted therapies for patients who are not helped by currently available drugs.